ClinicalTrials.gg
RecruitingNCT07653958Updated Jun 22, 2026

Risk Factor Assessment for Acute Pulmonary Hypertension Crisis

An observational study in Pulmonary Hypertension and Pulmonary Hypertension Crisis, sponsored by Peking Union Medical College Hospital. Recruiting at 4 sites in China. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Peking Union Medical College Hospital · Observational

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
5,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 85 studies in Hypertension, Pulmonary with a site in China — 31 open to participants now, 36 under way, 5 of them phase 3. Hypertension, Pulmonary · China.

Planned enrollment
4th of 36
5,000 · median 750
Started
2026
with 4 others
Observational
36 of 85
18 open now
Primary completion
2029-06
later than 31 of 35 live
Registered
82nd of 85
by date

Among the 85 studies in Hypertension, Pulmonary with a site in China, this one is the 4th largest by planned enrollment of the 36 observational ones that give a count, is one of 5 that started in 2026, is one of 36 observational ones, reaches primary completion later than 31 of the 35 other live ones, and was the 82nd registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

31 of the 85 studies in Hypertension, Pulmonary with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.

This study: all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Hypertension, Pulmonary with a site in China, or all of them as a file.
02

Study summary

The goal of this observational study is to learn about pulmonary hypertension crisis (PHC) - a severe, and often fatal complication - in patients with pulmonary hypertension (PH). The main questions this study aims to answer are:

What are the clinical and hemodynamic features of PHC, and what underlying pathophysiological mechanisms cause it to develop? Can these features be used to diagnostic PHC, predict who is at risk of developing it or dying from it, and develop targeted prevention and treatment of PHC?

A multi-center registry platform and biobank will be established to enroll and follow up patients with PH. Clinical data, hemodynamic measurements, and biological specimen will be collected. Risk prediction and early warning tools of PHC will be developed.

Read the detailed description

Pulmonary hypertension crisis (PHC) is a severe and fatal complication of pulmonary hypertension (PH), characterized by the sudden elevation of pulmonary vascular resistance, acute right hear failure and collapse of systemic circulation. However, PHC currently lacks any internationally accepted definition or diagnostic criteria, and it is still unclear which are the clinical, pathophysiological and molecular risk factors of PHC.

This study aims to establish a large clinical cohort of patients with PH, validate the definition of PHC, identify risk factors of PHC occurrence and mortality, and develop tools for the risk-prediction and early-warning of PHC.

This is a multi-center, prospective cohort study with a retrospective component for model training. Following national health-information standards, a standardized registry dataset will be established to cover demographics, clinical features, laboratory tests, imaging, and hemodynamic profile. Existing PH cohort databases will be integrated and expanded to a target of 5,000 patients. A subset of cases with right heart catheter parameters (RHC) will be extracted. A multi-center biospecimen management platform will be established.

For PHC onset, the investigators will assemble a clinical-molecular-imaging feature set and use convolutional neural networks and tree-based algorithms for feature extraction, then build a cross-modal prediction model using multi-task learning, neural networks, and a Transformer architecture. The model will be prospectively validated and tuned against real-world performance. For PHC mortality, models will be built on patients meeting the new PHC criteria, using 28-day attributable death, all-cause death, and long-term death as endpoints. Models will be trained on a retrospective cohort and then evaluated for accuracy and generalizability on both an internal validation set and an external prospective-cohort validation set.

03

Conditions studied

  • Pulmonary Hypertension
  • Pulmonary Hypertension Crisis

Keywords

  • Pulmonary hypertension
  • Pulmonary hypertension crisis
  • Diagnosis
  • Risk factor
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients with pulmonary hypertension confirmed by right heart catheterization

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pulmonary hypertension confirmed by mean pulmonary arterial pressure (mPAP) over 20 mmHg measured by right heart catheter
  • At least once per year of follow-up data collection record

Exclusion criteria

Exclusion Criteria:

  • Patients with missing baseline or follow-up data
  • Complicated by other diseases with significant influence on survival, such as acute coronary syndrome, , etc.
  • Complicated by other diseases with significant influence on hemodynamics, such as sepsis, acute left heart failure, and acute pulmonary embolism, etc.
  • Receiving medications with significant influence on hemodynamics
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
5,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Pulmonary hypertension

    Patients with right heart catheter confirmed pulmonary hypertension

06

What researchers measure

Primary outcomes

  1. Pulmonary hypertension crisis

    Critical increase of pulmonary vascular resistance accompanied by right heart dysfunction and systemic hypoperfusion

    Time frame: From enrollment to 3 years after enrollment

  2. 28 day mortality attributed to pulmonary hypertension crisis

    Death attributed to pulmonary hypertension crisis within 28 days of hospitalization

    Time frame: From hospitalization to 28 days

Secondary outcomes

  1. All cause mortality within hospitalization

    All cause death within hospitalization

    Time frame: From hospitalization to discharge or documented death, whichever is earlier, assessed up to 3 years

  2. All cause mortality within 3 years

    All cause death within 3 years from the diagnosis of pulmonary hypertension crisis

    Time frame: From the diagnosis of pulmonary hypertension crisis to documented death, assessed up to 3 years

07

Study locations

4 of 4 sites recruiting
08

References and documents

Publications

  • Qu J, Li M, Zhang X, Zhang M, Zuo X, Zhu P, Ye S, Zhang W, Zheng Y, Qi W, Li Y, Zhang Z, Ding F, Gu J, Liu Y, Qian J, Huang C, Zhao J, Wang Q, Liu Y, Tian Z, Wang Y, Wei W, Zeng X. A prognostic model for systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study. Respir Res. 2023 Sep 9;24(1):220. doi: 10.1186/s12931-023-02522-2. PubMed 37689662 ↗
  • Qian J, Li M, Zhang X, Wang Q, Zhao J, Tian Z, Wei W, Zuo X, Zhang M, Zhu P, Ye S, Zhang W, Zheng Y, Qi W, Li Y, Zhang Z, Ding F, Gu J, Liu Y, Wang Y, Zeng X; following investigators were collaborators in the CSTAR-PAH study:. Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study. Eur Respir J. 2019 Feb 14;53(2):1800081. doi: 10.1183/13993003.00081-2018. Print 2019 Feb. PubMed 30635295 ↗
  • Hemnes AR, Beck GJ, Newman JH, Abidov A, Aldred MA, Barnard J, Berman Rosenzweig E, Borlaug BA, Chung WK, Comhair SAA, Erzurum SC, Frantz RP, Gray MP, Grunig G, Hassoun PM, Hill NS, Horn EM, Hu B, Lempel JK, Maron BA, Mathai SC, Olman MA, Rischard FP, Systrom DM, Tang WHW, Waxman AB, Xiao L, Yuan JX, Leopold JA; PVDOMICS Study Group. PVDOMICS: A Multi-Center Study to Improve Understanding of Pulmonary Vascular Disease Through Phenomics. Circ Res. 2017 Oct 27;121(10):1136-1139. doi: 10.1161/CIRCRESAHA.117.311737. PubMed 29074534 ↗
  • Boucly A, Song S, Keles M, Wang D, Howard LS, Humbert M, Sitbon O, Lawrie A, Thompson AAR, Frank P, Kivimaki M, Rhodes CJ, Wilkins MR. Clustering Patients with Pulmonary Hypertension Using the Plasma Proteome. Am J Respir Crit Care Med. 2025 Aug;211(8):1492-1503. doi: 10.1164/rccm.202408-1574OC. PubMed 40344188 ↗

Individual participant data

Plan to share: Yes — IPD that underlie the results reported in our publications will be shared after de-identification, including clinical, hemodynamic, laboratory, and imaging data (tables, figures, and appendices).

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Beginning 1 year after publication with no end date

Access criteria: Researchers who submit a methodologically sound proposal will be able to access the de-identified individual participant data and supporting documents. Proposals should be directed to the principal investigator at pjm731@hotmail.com. To gain access, requestors will be required to sign a data access agreement, and data will be shared for the purpose of achieving the aims in the approved proposal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2029, 36 months after the start.

Of 142 non-industry observational studies under Hypertension, Pulmonary, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 167. This study's planned 36 months is below that.

Counting every sponsor, half of 167 studies reached it within 59 months; a quarter within 24 and three quarters within 107.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2026
First posted
Jun 17, 2026
StartActual
Jun 17, 2026
Primary completionEst.
Jun 30, 2029
CompletionEst.
Dec 31, 2029
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07653958
Responsible party
Sponsor
First posted
Jun 17, 2026
Start date
Jun 17, 2026
Primary completion
Jun 30, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Jun 22, 2026

Study contacts

Run Dong, MD
Contact
dongrun5858@foxmail.com
861069155036
Jinmin Peng, MD
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion